LUNG CANCER

Sunvozertinib is FDA approved for patients with NSCLC with EGFR exon 20 insertion mutations that progressed on or after platinum-based chemotherapy.

Vopimetostat yielded favorable outcomes in a phase 1/2 trial in combination with daraxonrasib or zoldonrasib in MTAP-deleted, RAS-mutant pancreatic cancer or lung cancer.

During a live event, Mary Jo Fidler, MD, and participants discussed how an intermediate-risk regimen, insurance resistance, and limited experience with trilaciclib shape neutropenia prevention in extensive-stage disease.

A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.

Theodore Wagener, PhD, of The Ohio State University discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.

FDA grants 2 breakthrough therapy designations to Temab-A, speeding development for hard-to-treat colorectal cancer and c-Met–expressing lung cancer.

Lyudmila Bazhenova, MD, explains why the updated taletrectinib label does not change her practice and reviews new WCLC subgroup data in ROS1+ NSCLC.

Firmonertinib did not improve PFS in the phase 3 FURVENT trial in patients with EGFR exon 20 insertion–mutant NSCLC.

Submission of a new drug application for zipalertinib plus chemotherapy has begun under the FDA's RTOR program, based on phase 3 REZILIENT3 data showing a 6-month PFS gain.

FDA fast-tracks plinabulin plus docetaxel for post-immunotherapy non-squamous NSCLC, as DUBLIN-4 phase 3 targets survival gains.

US cancer deaths keep falling as lung cancer declines; smoking drops, screening rises, but rural and low-education gaps persist.

Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.

David DiBardino, MD, explains how a hafnium compound is being tested alongside chemoradiation and durvalumab to address low response rates in locally advanced disease.

David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.

The COPERNICUS study of amivantamab/lazertinib showed lower rates of adverse events and discontinuation with supportive care regimens in patients with EGFR-mutated non–small cell lung cancer.

The FDA approved an sNDA updating the taletrectinib label with a 49.7-month median duration of response from TRUST-I in ROS1-positive NSCLC.

KEYNOTE-D46 shows sacituzumab govitecan plus pembrolizumab misses PFS/OS targets in PD-L1–high metastatic NSCLC, despite higher responses and toxicity.

Jonathan Villena-Vargas, MD, explains how a rib-sparing robotic approach cuts post-thoracotomy pain and opioid use for thoracic surgery patients.

The phase 3 DESTINY-Lung04 trial showed first-line trastuzumab deruxtecan extended PFS in patients with HER2-mutant NSCLC.

Updated PRESERVE-003 data showed gotistobart nearly doubled median OS vs docetaxel in previously treated squamous NSCLC.

Osimertinib was associated with a 47% reduction in risk of death among patients with stage II-IIIA EGFR-mutated non–small cell lung cancer at 8 years.

First-line amivantamab plus chemotherapy produced the longest reported median OS in EGFR exon 20 insertion-positive advanced NSCLC in the phase 3 PAPILLON trial.

ARROS-1 data show zidesamtinib drives 94% responses in untreated ROS1+ NSCLC, including brain metastases, supporting first-line FDA filing.

A single blood draw 3 to 9 weeks into immunotherapy predicted survival outcomes in metastatic non–small cell lung cancer, according to a new Johns Hopkins study.

Gavin Wright, MBBS, explains what the phase 3 VISUALIZE 2 trial aims to confirm about abenacianine's surgical benefit for patients with lung cancer.